Prima BioMed (IMMP) Competitors $0.49 +0.01 (+1.17%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.48 0.00 (-1.01%) As of 05/22/2026 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock IMMP vs. AMRN, SIGA, RGNX, NGEN, and ELDNShould you buy Prima BioMed stock or one of its competitors? MarketBeat compares Prima BioMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prima BioMed include Amarin (AMRN), Siga Technologies (SIGA), REGENXBIO (RGNX), NervGen Pharma (NGEN), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. IMMP vs. AMRNIMMP vs. SIGAIMMP vs. RGNXIMMP vs. NGENIMMP vs. ELDNHow does Prima BioMed compare to Amarin?Amarin (NASDAQ:AMRN) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends. Do insiders & institutionals believe in AMRN or IMMP? 22.3% of Amarin shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 3.1% of Prima BioMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is AMRN or IMMP more profitable? Prima BioMed has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Prima BioMed's return on equity of 0.00% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Amarin-15.51% -2.99% -2.07% Prima BioMed N/A N/A N/A Do analysts rate AMRN or IMMP? Amarin currently has a consensus price target of $12.00, indicating a potential downside of 16.84%. Prima BioMed has a consensus price target of $5.50, indicating a potential upside of 1,031.92%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Prima BioMed is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33Prima BioMed 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Does the media favor AMRN or IMMP? In the previous week, Prima BioMed had 14 more articles in the media than Amarin. MarketBeat recorded 16 mentions for Prima BioMed and 2 mentions for Amarin. Prima BioMed's average media sentiment score of 0.08 beat Amarin's score of -0.05 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, AMRN or IMMP? Amarin has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.24, indicating that its share price is 124% more volatile than the broader market. Which has higher earnings and valuation, AMRN or IMMP? Amarin has higher revenue and earnings than Prima BioMed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$213.65M1.42-$38.80M-$0.65N/APrima BioMed$6.69M10.70-$39.78MN/AN/A SummaryPrima BioMed beats Amarin on 9 of the 13 factors compared between the two stocks.How does Prima BioMed compare to Siga Technologies?Siga Technologies (NASDAQ:SIGA) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation. Which has more risk and volatility, SIGA or IMMP? Siga Technologies has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.24, indicating that its stock price is 124% more volatile than the broader market. Do analysts rate SIGA or IMMP? Prima BioMed has a consensus target price of $5.50, indicating a potential upside of 1,031.92%. Given Prima BioMed's higher possible upside, analysts clearly believe Prima BioMed is more favorable than Siga Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Prima BioMed 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Is SIGA or IMMP more profitable? Siga Technologies has a net margin of 21.58% compared to Prima BioMed's net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat Prima BioMed's return on equity.Company Net Margins Return on Equity Return on Assets Siga Technologies21.58% 10.60% 8.94% Prima BioMed N/A N/A N/A Do insiders and institutionals believe in SIGA or IMMP? 55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 2.7% of Siga Technologies shares are held by insiders. Comparatively, 3.1% of Prima BioMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor SIGA or IMMP? In the previous week, Prima BioMed had 15 more articles in the media than Siga Technologies. MarketBeat recorded 16 mentions for Prima BioMed and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.45 beat Prima BioMed's score of 0.08 indicating that Siga Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, SIGA or IMMP? Siga Technologies has higher revenue and earnings than Prima BioMed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSiga Technologies$94.57M3.55$23.28M$0.2717.33Prima BioMed$6.69M10.70-$39.78MN/AN/A SummarySiga Technologies beats Prima BioMed on 8 of the 13 factors compared between the two stocks.How does Prima BioMed compare to REGENXBIO?REGENXBIO (NASDAQ:RGNX) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability. Which has more volatility & risk, RGNX or IMMP? REGENXBIO has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market. Do institutionals & insiders have more ownership in RGNX or IMMP? 88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 3.1% of Prima BioMed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is RGNX or IMMP more profitable? Prima BioMed has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Prima BioMed's return on equity of 0.00% beat REGENXBIO's return on equity.Company Net Margins Return on Equity Return on Assets REGENXBIO-330.23% -232.50% -61.02% Prima BioMed N/A N/A N/A Which has preferable earnings & valuation, RGNX or IMMP? Prima BioMed has lower revenue, but higher earnings than REGENXBIO. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioREGENXBIO$170.44M1.93-$193.88M-$5.60N/APrima BioMed$6.69M10.70-$39.78MN/AN/A Do analysts prefer RGNX or IMMP? REGENXBIO currently has a consensus price target of $23.91, suggesting a potential upside of 276.52%. Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,031.92%. Given Prima BioMed's higher probable upside, analysts plainly believe Prima BioMed is more favorable than REGENXBIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73Prima BioMed 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Does the media favor RGNX or IMMP? In the previous week, Prima BioMed had 12 more articles in the media than REGENXBIO. MarketBeat recorded 16 mentions for Prima BioMed and 4 mentions for REGENXBIO. Prima BioMed's average media sentiment score of 0.08 beat REGENXBIO's score of 0.04 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPrima BioMed beats REGENXBIO on 9 of the 14 factors compared between the two stocks.How does Prima BioMed compare to NervGen Pharma?Prima BioMed (NASDAQ:IMMP) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership. Does the media favor IMMP or NGEN? In the previous week, Prima BioMed had 2 more articles in the media than NervGen Pharma. MarketBeat recorded 16 mentions for Prima BioMed and 14 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of 0.37 beat Prima BioMed's score of 0.08 indicating that NervGen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NervGen Pharma 2 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of IMMP or NGEN? 2.3% of Prima BioMed shares are held by institutional investors. 3.1% of Prima BioMed shares are held by insiders. Comparatively, 5.8% of NervGen Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher earnings and valuation, IMMP or NGEN? NervGen Pharma has lower revenue, but higher earnings than Prima BioMed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$6.69M10.70-$39.78MN/AN/ANervGen PharmaN/AN/AN/AN/AN/A Do analysts prefer IMMP or NGEN? Prima BioMed presently has a consensus target price of $5.50, suggesting a potential upside of 1,031.92%. NervGen Pharma has a consensus target price of $18.00, suggesting a potential upside of 765.38%. Given Prima BioMed's higher possible upside, analysts plainly believe Prima BioMed is more favorable than NervGen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75NervGen Pharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 2.75 Is IMMP or NGEN more profitable? Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A NervGen Pharma N/A N/A N/A SummaryPrima BioMed and NervGen Pharma tied by winning 4 of the 8 factors compared between the two stocks.How does Prima BioMed compare to Eledon Pharmaceuticals?Prima BioMed (NASDAQ:IMMP) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation. Which has stronger valuation & earnings, IMMP or ELDN? Prima BioMed has higher revenue and earnings than Eledon Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$6.69M10.70-$39.78MN/AN/AEledon PharmaceuticalsN/AN/A-$45.62M-$0.77N/A Which has more risk & volatility, IMMP or ELDN? Prima BioMed has a beta of 2.24, indicating that its share price is 124% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Do insiders and institutionals have more ownership in IMMP or ELDN? 2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is IMMP or ELDN more profitable? Prima BioMed's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A Eledon Pharmaceuticals N/A -116.97%-41.91% Does the media prefer IMMP or ELDN? In the previous week, Prima BioMed had 14 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 16 mentions for Prima BioMed and 2 mentions for Eledon Pharmaceuticals. Prima BioMed's average media sentiment score of 0.08 beat Eledon Pharmaceuticals' score of -0.54 indicating that Prima BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Do analysts prefer IMMP or ELDN? Prima BioMed presently has a consensus price target of $5.50, indicating a potential upside of 1,031.92%. Eledon Pharmaceuticals has a consensus price target of $9.67, indicating a potential upside of 148.50%. Given Prima BioMed's higher possible upside, equities analysts plainly believe Prima BioMed is more favorable than Eledon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Eledon Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 SummaryPrima BioMed beats Eledon Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Get Prima BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition ExportMetricPrima BioMedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.61M$3.38B$6.44B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E RatioN/A18.9321.2625.66Price / Sales10.70323.66556.8487.32Price / CashN/A125.9643.6856.73Price / Book0.777.1110.367.14Net Income-$39.78M$24.45M$3.56B$335.80M7 Day Performance-6.50%3.32%5.12%3.02%1 Month Performance-15.20%2.52%3.54%2.48%1 Year Performance-74.95%63.09%34.14%35.08% Prima BioMed Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPPrima BioMed2.4543 of 5 stars$0.49+1.2%$5.50+1,031.9%-75.0%$71.61M$6.69MN/A2,021Trending NewsAMRNAmarin0.7341 of 5 stars$14.06-3.4%$12.00-14.7%+29.9%$305.31M$213.65MN/A360SIGASiga Technologies1.0766 of 5 stars$4.27+2.4%N/A-20.8%$299.09M$94.57M15.8140RGNXREGENXBIO3.0132 of 5 stars$5.65-1.2%$23.91+323.2%-34.6%$295.71M$170.44MN/A370NGENNervGen Pharma3.7225 of 5 stars$3.64+2.0%$18.00+394.5%N/A$293.50MN/AN/AN/ANews CoverageEarnings ReportAnalyst UpgradeGap Down Related Companies and Tools Related Companies Amarin Alternatives Siga Technologies Alternatives REGENXBIO Alternatives NervGen Pharma Alternatives Eledon Pharmaceuticals Alternatives Nuvectis Pharma Alternatives Niagen Bioscience Alternatives Zentalis Pharmaceuticals Alternatives Silence Therapeutics Alternatives Protara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMP) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
